Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival. (August 2021)

• Record Type: Journal Article
• Authors: Lien, Ming-Yu; Wang, Ti-Hao; Hsieh, Ching-Yun; Tsai, Ming-Hsui; Hua, Chun-Hung; Cheng, Fu-Ming; Chung, Wen-Hui; Tang, Chih-Hsin; Chia-Hsun Hsieh, Jason
• Is Part Of: Oral oncology. Volume 119(2021)
• Publication Date: 2021-08
• Subjects: Cetuximab -- Immune checkpoint inhibitor -- Head and neck cancer -- Platinum-resistance -- Recurrence -- Metastasis; Mouth -- Cancer -- Periodicals; Mouth -- Tumors -- Periodicals; Mouth Diseases -- Periodicals; Mouth Neoplasms -- Periodicals; Bouche -- Cancer -- Périodiques; Bouche -- Tumeurs -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9943105
• DOI: 10.1016/j.oraloncology.2021.105380
• Languages: English
• ISSNs: 1368-8375

Abstract

Highlights: We reported the real-world outcome of adding ICIs on/after cetuximab-based therapy. Survival was better in ICI combination or sequential groups than those without ICIs. Platinum sensitivity and responses of cetuximab are independent prognostic factors. Abstract: Background: After the introduction of ICI treatment, data about feasibility and activity of a cetuximab-containing first-line therapy in patients with recurrent and/or metastatic head and neck cancer (R/M HNSCC) are still not available. We sought to analyze the clinical outcomes in the real-world setting. Material Methods: This retrospective study was conducted at two tertiary medical centers in Taiwan. Patients with R/M HNSCC receiving cetuximab-containing first-line therapy were included between January 2017 and July 2019. The study endpoints were the response, Progression-Free Survival (PFS), and Overall Survival (OS). Subgroup analyses were conducted to evaluate survival outcomes by platinum resistance and the use of immunotherapy. Results: We identified 290 patients treated with cetuximab-containing first-line therapy. The most primary tumor site was oral cavity cancer (59.3%). 44% of patients were resistant to platinum. The median PFS and OS were 5.0 months and 9.1 months, respectively, for the total population. In patients with platinum resistance, the median OS was 10.4 months with ICIs versus 6.3 months without ICIs; p = 0.01. In patients with platinum sensitivity, the median OS was 20.6 months with ICIs versus 9.1 months without ICs; p < 0.01. OS benefit with ICIs was similar between patients who received ICIs after progression on Cetuximab and receiving Cetuximab in combination with ICIs. Independent favorable prognostic factors for OS were platinum-sensitive, better response to cetuximab, and ICIs use. Conclusion: ICIs are indicated to improve OS in R/M HNSCC receiving cetuximab-containing first-line therapy, even in platinum-resistant populations. The reduction in risk of death with ICIs was similar regarding the combination or sequencing of cetuximab.